{"id":67929,"date":"2026-06-10T21:22:42","date_gmt":"2026-06-10T13:22:42","guid":{"rendered":"https:\/\/flcube.com\/?p=67929"},"modified":"2026-06-10T21:22:43","modified_gmt":"2026-06-10T13:22:43","slug":"hengrui-pharmaceuticals-advances-triple-asset-breast-cancer-strategy-with-nmpa-approval-for-hrs-6209-combination-study-leveraging-selective-cdk4-inhibitor-and-novel-serd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67929","title":{"rendered":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced it has received regulatory clearance from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>Phase Ib\/II clinical study<\/strong> evaluating <strong>HRS-6209<\/strong> in combination with <strong>endocrine therapy and\/or HRS-9813<\/strong> in patients with <strong>HR-positive\/HER2-negative breast cancer<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company is advancing a comprehensive breast cancer pipeline featuring three distinct assets: <strong>HRS-6209<\/strong>, a <strong>novel selective CDK4 inhibitor<\/strong>; <strong>HRS-8080<\/strong>, a <strong>potent oral selective estrogen receptor degrader (SERD)<\/strong>; and <strong>HRS-9813<\/strong>, a <strong>Class 1 innovative drug<\/strong> with dual activity in oncology and pulmonary fibrosis. Multiple combination trials have progressed into <strong>Phase II\/III development<\/strong>, positioning Hengrui as a leading domestic player in breast cancer therapeutics.<\/p>\n\n\n\n<h2 id=\"h-pipeline-asset-profiles-amp-mechanisms\" class=\"wp-block-heading\">Pipeline Asset Profiles &amp; Mechanisms<\/h2>\n\n\n\n<h3 id=\"h-hrs-6209-selective-cdk4-inhibitor\" class=\"wp-block-heading\">HRS-6209: Selective CDK4 Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Potently inhibits cyclin-dependent kinase 4 (CDK4), suppresses Rb phosphorylation, induces G1 phase arrest<\/li>\n\n\n\n<li><strong>Selectivity Advantage<\/strong>: Improved CDK4 selectivity over CDK6 compared to existing CDK4\/6 inhibitors<\/li>\n\n\n\n<li><strong>Toxicity Profile<\/strong>: Potential mitigation of hematologic toxicities associated with current CDK4\/6 inhibitors<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Advanced malignant solid tumors, with focus on HR+\/HER2- breast cancer<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Phase Ib\/II combination studies approved<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hrs-8080-oral-selective-estrogen-receptor-degrader-serd\" class=\"wp-block-heading\">HRS-8080: Oral Selective Estrogen Receptor Degrader (SERD)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Potently and selectively degrades estrogen receptors (ER), inhibits ER activity and downstream signaling<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral formulation enabling convenient outpatient treatment<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: HR-positive breast cancer patients<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Multiple Phase II\/III trials actively underway<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hrs-9813-class-1-innovative-dual-activity-compound\" class=\"wp-block-heading\">HRS-9813: Class 1 Innovative Dual-Activity Compound<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Activity<\/strong>: Demonstrates synergistic antitumor effects with HRS-6209 in breast cancer xenograft models<\/li>\n\n\n\n<li><strong>Pulmonary Fibrosis<\/strong>: Significant improvement in mouse models with favorable safety profile<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Good overall tolerability in preclinical combination studies<\/li>\n\n\n\n<li><strong>Innovation Status<\/strong>: Independently developed Class 1 innovative drug by Hengrui<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Component<\/th><th>Design<\/th><th>Primary Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase Ib\/II Trial<\/strong><\/td><td>Combination therapy<\/td><td>Safety, tolerability, PK, preliminary efficacy<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>HR+\/HER2- breast cancer<\/td><td>Advanced\/metastatic disease<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>HRS-6209 + endocrine therapy \u00b1 HRS-9813<\/td><td>Optimal combination identification<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>China (NMPA-approved)<\/td><td>Potential global expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-differentiation-amp-market-position\" class=\"wp-block-heading\">Competitive Differentiation &amp; Market Position<\/h2>\n\n\n\n<h3 id=\"h-cdk4-6-inhibitor-landscape\" class=\"wp-block-heading\">CDK4\/6 Inhibitor Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Market<\/strong>: Dominated by palbociclib, ribociclib, and abemaciclib with established efficacy but significant hematologic toxicity<\/li>\n\n\n\n<li><strong>HRS-6209 Advantage<\/strong>: Enhanced CDK4 selectivity potentially reducing neutropenia and other blood-related adverse events<\/li>\n\n\n\n<li><strong>Combination Strategy<\/strong>: Triple-combination approach (CDK4i + SERD + novel agent) addressing multiple resistance mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-serd-competition\" class=\"wp-block-heading\">SERD Competition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral SERD Market<\/strong>: Highly competitive space with multiple candidates in late-stage development<\/li>\n\n\n\n<li><strong>HRS-8080 Positioning<\/strong>: Part of integrated combination strategy rather than standalone therapy<\/li>\n\n\n\n<li><strong>Domestic Leadership<\/strong>: Among the most advanced Chinese-developed SERDs in clinical development<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-advantages\" class=\"wp-block-heading\">Strategic Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integrated Pipeline<\/strong>: Three complementary assets enabling comprehensive combination strategies<\/li>\n\n\n\n<li><strong>Dual Indication Potential<\/strong>: HRS-9813&#8217;s activity in both oncology and fibrotic diseases provides portfolio diversification<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong>: Multiple assets progressing through Chinese regulatory system with potential global expansion<\/li>\n\n\n\n<li><strong>Manufacturing Control<\/strong>: Fully independent development reduces supply chain and IP risks<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-outlook\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HR+\/HER2- Breast Cancer<\/strong>: Represents approximately 70% of all breast cancer cases globally<\/li>\n\n\n\n<li><strong>Chinese Market Size<\/strong>: Estimated 300,000+ new HR+\/HER2- breast cancer cases annually in China<\/li>\n\n\n\n<li><strong>CDK4\/6 Inhibitor Market<\/strong>: Projected to reach $15 billion globally by 2028<\/li>\n\n\n\n<li><strong>Oral SERD Market<\/strong>: Expected to capture significant share from fulvestrant and traditional endocrine therapies<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Analysts project peak annual sales of $800 million-$1.2 billion for Hengrui&#8217;s breast cancer franchise<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This multi-asset approach demonstrates Hengrui&#8217;s sophisticated understanding of breast cancer biology and resistance mechanisms, positioning the company to compete effectively in one of oncology&#8217;s most valuable therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, competitive positioning, and revenue projections. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260610_ANWY.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260610_ANWY.\"><\/object><a id=\"wp-block-file--media-9826f99d-8c6f-4f82-bf5a-a6186468a9ed\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260610_ANWY.pdf\">600276_20260610_ANWY<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260610_ANWY.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9826f99d-8c6f-4f82-bf5a-a6186468a9ed\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2586,4228,852],"class_list":["post-67929","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China&#039;s National Medical Products Administration (NMPA) to initiate a Phase Ib\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\/or HRS-9813 in patients with HR-positive\/HER2-negative breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67929\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China&#039;s National Medical Products Administration (NMPA) to initiate a Phase Ib\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\/or HRS-9813 in patients with HR-positive\/HER2-negative breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67929\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T13:22:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T13:22:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD\",\"datePublished\":\"2026-06-10T13:22:42+00:00\",\"dateModified\":\"2026-06-10T13:22:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929\"},\"wordCount\":607,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67929#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67929\",\"name\":\"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-10T13:22:42+00:00\",\"dateModified\":\"2026-06-10T13:22:43+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a Phase Ib\\\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\\\/or HRS-9813 in patients with HR-positive\\\/HER2-negative breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67929\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67929#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a Phase Ib\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\/or HRS-9813 in patients with HR-positive\/HER2-negative breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67929","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a Phase Ib\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\/or HRS-9813 in patients with HR-positive\/HER2-negative breast cancer.","og_url":"https:\/\/flcube.com\/?p=67929","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T13:22:42+00:00","article_modified_time":"2026-06-10T13:22:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67929#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67929"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD","datePublished":"2026-06-10T13:22:42+00:00","dateModified":"2026-06-10T13:22:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67929"},"wordCount":607,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67929#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67929","url":"https:\/\/flcube.com\/?p=67929","name":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-10T13:22:42+00:00","dateModified":"2026-06-10T13:22:43+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a Phase Ib\/II clinical study evaluating HRS-6209 in combination with endocrine therapy and\/or HRS-9813 in patients with HR-positive\/HER2-negative breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67929#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67929"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67929#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67929"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67929\/revisions"}],"predecessor-version":[{"id":67931,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67929\/revisions\/67931"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}